Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

novo nordisk a/s, novo alle, bagsvaerd, danska - estradiol hemihidrat - tableta za rodnicu - 10 mikrograma - urbroj: jedna tableta za rodnicu sadrži: estradiol hemihidrat što je ekvivalentno 10 mikrograma estradiola

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

ucb pharma s.a., allée de la recherche 60, anderlecht (bruxelles), belgija - levocetirizindiklorid - filmom obložena tableta - 5 mg - urbroj: jedna filmom obložena tableta sadrži 5 mg levocetirizindiklorida

Europska Unija - hrvatski - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - karcinom, ne-malih stanica pluća - antineoplastična sredstva - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - drugi antineoplastični agensi - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

mylan s.a.s., 117 allee des parcs, saint priest, francuska - aripiprazolum - tableta - 10 mg - urbroj: jedna tableta sadrži 10 mg aripiprazola

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

mylan s.a.s., 117 allee des parcs, saint priest, francuska - aripiprazolum - tableta - 15 mg - urbroj: svaka tableta sadrži 15 mg aripiprazola

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

mylan s.a.s., 117 allee des parcs, saint priest, francuska - aripiprazolum - tableta - 30 mg - urbroj: jedna tableta sadrži 30 mg aripiprazola

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

novo nordisk a/s, novo alle, bagsvaerd, danska - glukagonklorid - prašak i otapalo za otopinu za injekciju - 1 mg - urbroj: jedna bočica sadrži 1 mg glukagona u obliku klorida, što odgovara 1 mg (1 iu) glukagona/ml nakon rekonstitucije

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

alk-abelló a/s, boge allé 6-8, horsholm, danska - standardizirani ekstrakt alergena peludi bijele breze - sublingvalni liofilizat - 12 sq-bet - urbroj: jedan sublingvalni liofilizat sadrži 12 sq-bet standardiziranog alergena ekstrakta peludi bijele breze (betula verrucosa)

Europska Unija - hrvatski - EMA (European Medicines Agency)

orphelia pharma sas - clofarabine - prekursorska stanica limfoblastične leukemije-limfom - antineoplastična sredstva - liječenje akutne limfoblastične leukemije (all) u pedijatrijskih bolesnika koji imaju relapsed ili su vatrostalne nakon najmanje dva prethodnog režima i gdje nema drugih mogućnost liječenja predviđa da će rezultirati trajan odgovor. sigurnost i učinkovitost procijenjeni su u ispitivanjima bolesnika ≤ 21 godina kod početne dijagnoze.